Clinics is a gold open access electronic international journal that publishes peer-reviewed research in continuous flow of interest to clinicians and researchers in medical and biomedical sciences based on its originality, importance, conclusions and interest to readers. CLINICS also publishes Comments and Editorials. The journal is committed to the principles of ethics, respect for the individual, humanization, honesty, pioneering spirit and excellence.Clinics is the Official Scientific journal of Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP).
Indexed in:
Clarivate/ISI: Web of Sciences, SCOPUS, PubMed Central (PMC), SciELO Brasil, SciELO Public Health, Redalyc, EMBASE, Nutrition Abstracts & Reviews, POPLINE, Tropical Diseases Bulletin, LILACS
See moreFollow us:
The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.
© Clarivate Analytics, Journal Citation Reports 2022
SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.
See moreSNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.
See more- •
This meta-analysis shows that gefitinib plus chemotherapy showed significantly better efficacy in improving objective response rate, disease control rate, progression-free survival, and OS as compared with gefitinib alone.
- •
Similar efficacy of gefitinib plus chemotherapy is found in the sub-population with positive EGFR mutation.
- •
The toxicity of gefitinib plus chemotherapy is also increased but within clinical management.
• Prevalence of dysarthria in SPG4 is greater than previously considered.
• The dysarthria in SPG4 is mild or moderate.
• The subsystems of speech more affected are articulatory and phonation.
- •
Liver abscess patients with diabetes mellitus have featured presentations.
- •
Liver abscess patients with diabetes mellitus have featured changes after therapy.
- •
Liver abscess patients with diabetes mellitus cannot have a better therapeutic effect.
- •
Lnc-ZFAS1 is highly expressed in osteosarcoma.
- •
Lnc-ZFAS1 could promote cell proliferation, migration, invasion and EMT in vitro.
- •
Lnc-ZFAS1 acted sponger of miR-520b and miR-520e to promote RHOC.
- •
Desmoid Tumors in Familial Adenomatous Polyposis are a huge problem in these patients, the ability to prevent desmoid development is limited.
- •
Some clinical and surgical variables were identified as unfavorable and associated with a greater risk.
- •
This variable may be useful during the decision-making process.
- •
This meta-analysis shows that gefitinib plus chemotherapy showed significantly better efficacy in improving objective response rate, disease control rate, progression-free survival, and OS as compared with gefitinib alone.
- •
Similar efficacy of gefitinib plus chemotherapy is found in the sub-population with positive EGFR mutation.
- •
The toxicity of gefitinib plus chemotherapy is also increased but within clinical management.
- •
There is no consensus about which method is preferred for biliary drainage for Perihilar Cholangiocarcinoma (PCCA).
- •
Endoscopic retrograde cholangiopancreatography (EBD) or Percutaneous Transhepatic Biliary Drainage (PTBD) are options of choice.
- •
PTBD is superior to EBD regarding crossover rate, overall post-drainage complications, and post-drainage pancreatitis.
- •
EBD is superior to PTBD when it comes to hospital length of stay.
- •
For the palliation of PCCA, PTBD is superior to EBD in terms of clinical success and post-drainage cholangitis.
- •
Children with hemoglobinopathies have less severe conditions with Coronavirus 2019 Disease (COVID-19) compared to adults, which is similar to that observed in the general population
- •
In the H1N1 pandemic, patients with hemoglobinopathies behaved as the group most susceptible to complications, with increased morbidity and mortality
- •
A meta-analysis was applied to understand the relationship between inhibition of Toll-like Receptor 4 and diabetic myocardial injury.
- •
Inhibition of Toll-like Receptor 4 expression levels can improve the degree of cardiac impairment.
- •
Toll-like Receptor 4 may become a new target for the treatment of diabetic cardiomyopathy.
- Home
- All contents
- Publish your article
- About the journal
- Metrics